Seres Therapeutics' (MCRB) CEO Roger Pomerantz on Q1 2018 Results - Earnings Call Transcript [Seeking Alpha]
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: Seeking Alpha
Seres Therapeutics, Inc. (NASDAQ: MCRB ) Q1 2018 Earnings Conference Call May 9, 2018 8:30 AM ET Executives Carlo Tanzi - Head, IR & Corporate Communications Roger Pomerantz - President & CEO Eric Shaff - COO, CFO, Executive VP & Principal Accounting Officer Analysts Jason Jakoby - Goldman Sachs Pamela Barendt - Cowen and Company Mark Breidenbach - Oppenheimer Operator Good day, ladies and gentlemen, and welcome to the First Quarter 2018 Seres Therapeutics Earnings Conference Call. [Operator Instructions]. As a reminder this call is being recorded. I would now like to introduce your host for today's conference Carlo Tanzi, Vice President, Investor Relations and Corporate Communications. Sir, you may begin. Carlo Tanzi Thank you, and good morning. A press release with the company's first quarter 2018 financial results and a business update became available at 7 A.M. Eastern Time this morning and can be found on the Investors & Media section of the
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Microbiome Manufacturing Market Trends and Global Forecasts, 2035 - Close to 170 Trials are Evaluating Microbiome Therapeutics to Treat Various Infectious Diseases and Oncological Disorders [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $9.00 to $5.00. They now have an "outperform" rating on the stock.MarketBeat
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Chardan Capital from $10.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023 [Yahoo! Finance]Yahoo! Finance
MCRB
Earnings
- 11/2/23 - Beat
MCRB
Sec Filings
- 3/27/24 - Form 4
- 3/27/24 - Form 3
- 3/5/24 - Form DEF
- MCRB's page on the SEC website